Adequan® i.m. (Polysulfated Glycosaminoglycan) is proven to reach peak therapeutic levels in joints within 2 hours to:
Relieve pain and reduce inflammation of the synovial membrane.
Inhibit destructive enzymes that attack the synovial fluid and cartilage.
Stimulate cartilage repair by blocking destructive enzymes Adequan® i.m. is detected in cartilage and subchondral bone up to 4 days after a single injection. The health of the cartilage is critical to the performance of the joint.
Reverse degenerative joint disease to help restore the natural balanced wear and repair cycle within the joint.
Proven to relieve symptoms of non-infectious osteoarthritis, Adequan® i.m. is the only FDA-approved treatment to stop the destructive disease cycle, stimulate cartilage repair and reverse the joint disease process. Administered intramuscularly, Adequan® i.m. is a potent enzyme inhibitor that travels to traumatized knee or hock joints. Extensive studies of Adequan® i.m. have proven it readily passes through the synovial membrane and is taken up into cartilage where it concentrates and accumulates at the site of injury.
There are no known contraindications to the use of intramuscular PSGAG in horses. Studies have not been conducted to establish safety in breeding horses. Not for use in humans. Keep this and all medications out of the reach of children. See product package insert for full prescribing information.